These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 16815858

  • 1. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [Abstract] [Full Text] [Related]

  • 2. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group.
    N Engl J Med; 2003 Aug 28; 349(9):847-58. PubMed ID: 12944570
    [Abstract] [Full Text] [Related]

  • 3. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H, Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 28; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [Abstract] [Full Text] [Related]

  • 4. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpón LA, Renlund D, Abeywickrama K, Cretin N, Starling RC, Eisen HJ, RAD B253 Study Group.
    J Heart Lung Transplant; 2007 Jun 28; 26(6):584-92. PubMed ID: 17543781
    [Abstract] [Full Text] [Related]

  • 5. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H, Ross H.
    J Heart Lung Transplant; 2004 May 28; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [Abstract] [Full Text] [Related]

  • 6. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
    Valantine H.
    J Heart Lung Transplant; 2005 Apr 28; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
    [Abstract] [Full Text] [Related]

  • 7. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L.
    Transplantation; 2011 Jul 27; 92(2):235-43. PubMed ID: 21677600
    [Abstract] [Full Text] [Related]

  • 8. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [Abstract] [Full Text] [Related]

  • 9. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H, Hetzer R.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [Abstract] [Full Text] [Related]

  • 10. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
    Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D.
    Transplant Proc; 2005 May 27; 37(4 Suppl):4S-17S. PubMed ID: 15809102
    [Abstract] [Full Text] [Related]

  • 11. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.
    Krämer BK, Neumayer HH, Stahl R, Pietrzyk M, Krüger B, Pfalzer B, Bourbigot B, Campbell S, Whelchel J, Eris J, Vitko S, Budde K, RADA2307 Study Group.
    Transplant Proc; 2005 Apr 27; 37(3):1601-4. PubMed ID: 15866684
    [Abstract] [Full Text] [Related]

  • 12. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation.
    Annemans L, Lemkuhl H, Tenderich G, Schulz U, Yang XL, Ricci JF, Hetzer R.
    Transplant Proc; 2007 Dec 27; 39(10):3306-12. PubMed ID: 18089377
    [Abstract] [Full Text] [Related]

  • 13. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 27; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 14. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
    Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, Macdonald P, Esmore D, Muller D, Faddy S.
    Circulation; 2004 Oct 26; 110(17):2694-700. PubMed ID: 15262845
    [Abstract] [Full Text] [Related]

  • 15. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.
    Transpl Infect Dis; 2013 Apr 26; 15(2):150-62. PubMed ID: 23013440
    [Abstract] [Full Text] [Related]

  • 16. Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation.
    Radeva JI, Reed SD, Kaló Z, Kauf TL, Cantu E, Cretin N, Schulman KA.
    Clin Transplant; 2005 Feb 26; 19(1):122-9. PubMed ID: 15659145
    [Abstract] [Full Text] [Related]

  • 17. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?
    Zuckermann A, Wang SS, Epailly E, Barten MJ, Sigurdardottir V, Segovia J, Varnous S, Turazza FM, Potena L, Lehmkuhl HB.
    Transplant Rev (Orlando); 2013 Jul 26; 27(3):76-84. PubMed ID: 23643624
    [Abstract] [Full Text] [Related]

  • 18. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
    Kovarik JM.
    Drugs Today (Barc); 2004 Feb 26; 40(2):101-9. PubMed ID: 15045032
    [Abstract] [Full Text] [Related]

  • 19. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M, Tscheliessnigg K.
    Transpl Immunol; 2006 Jun 26; 16(1):46-51. PubMed ID: 16701176
    [Abstract] [Full Text] [Related]

  • 20. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.
    Transplantation; 2020 Jan 26; 104(1):154-164. PubMed ID: 30893292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.